Extracted from this filing and checked against the source text.
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
HeartSciences Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).
- Exchange
- nasdaq
- Notice
- noncompliance notice
- Deficiency
- minimum bid price
- Rules
- 5550(a)(2)
Exact text from the filing
August 1, 2023, the Staff notified the Company that the bid price of its common stock failed to close above the minimum $1 requirement for the past 30 trading days, pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The Company attended an August 17, 2023, hearing before the Panel and requested the continued listing of its securities on the Nasdaq Capital Market pending its return to compliance with the Equity Rule and the Bid Price Rule. On August 28, 2023, the Company received a decision from the Panel granting the Company’s request for continued listing on the Nasdaq Capital
View on SEC.gov
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
HeartSciences Inc. received a nasdaq hearing update notice regarding stockholders equity (rules 5250(b)(1)).
- Exchange
- nasdaq
- Notice
- hearing update
- Deficiency
- stockholders equity
- Rules
- 5250(b)(1)
Exact text from the filing
August 28, 2023, the Company received a decision from the Panel granting the Company’s request for continued listing on the Nasdaq Capital Market, subject to the Company demonstrating compliance with the Equity Rule on or before November 21, 2023, and certain other conditions. In addition, The Company has until January 29, 2024, to demonstrate compliance with the minimum $1 bid price requirement pursuant to the Bid Price Rule. Statements contained herein relating to the Company or its management’s intentions, hopes, beliefs, expectations or predictions of the future, including, but not limited
View on SEC.gov